The purpose of this review is to describe antifungal therapeutic candidates in preclinical and clinical development derived from, or directly influenced by, the immune system, with a specific focus on antimicrobial peptides (AMP). Although the focus of this review is AMP with direct antimicrobial effects on fungi, we will also discuss compounds with direct antifungal activity, including monoclonal antibodies (mAb), as well as immunomodulatory molecules that can enhance the immune response to fungal infection, including immunomodulatory AMP, vaccines, checkpoint inhibitors, interferon and colony stimulating factors as well as immune cell therapies. The focus of this manuscript will be a non-exhaustive review of antifungal compounds in preclinical and clinical development that are based on the principles of immunology and the authors acknowledge the incredible amount of in vitro and in vivo work that has been conducted to develop such therapeutic candidates.

这篇综述的目的是描述源自免疫系统或直接受免疫系统影响的临床前和临床开发中的抗真菌治疗候选物，特别关注抗微生物肽（AMP）。尽管本综述的重点是对真菌具有直接抗菌作用的AMP，但我们还将讨论具有直接抗真菌活性的化合物，包括单克隆抗体（mAb）以及可增强对真菌感染的免疫应答的免疫调节分子，包括免疫调节AMP ，疫苗，检查点抑制剂，干扰素和集落刺激因子以及免疫细胞疗法。体外 和 体内 为开发这类治疗性候选物而进行的工作。